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1. Introduction 
Protein kinase A (PKA) is a ubiquitous serine-threonine kinase that is activated by adenyl 
cyclase (AC)-mediated cAMP (Niswender et al., 1975).  Canonically, the PKA signaling 
pathway is triggered  when G-coupled receptors, a family of seven transmembrane domain 
proteins,  are bound by extracellular hormones. The resultant dissociation of the Gs complex 
allows the stimulatory Gs┙ protein to bind to and activate membrane-bound adenylyl 
cyclases (ACs), which convert ATP to cAMP.  The PKA holoenzyme has four subunits: 2 of 
which are catalytic (PKA C) and two of which are regulatory (PKA R).  When associated, the 
heteroterameric enzyme is inactive.  When cAMP binds to the regulatory subunits, the PKA 
C monomers are released, becoming catalytically active (Kirschner et al., 2009) (Fig. 1).   
 
 
Fig. 1. cAMP activation of PKA.   
PKA plays a role in numerous biological functions, with hundreds of PKA substrates 
identified in both the cytoplasm as well as the nucleus (Budovskaya et al., 2005; Huang et 
al., 2007; Neuberger et al., 2007; Gao et al., 2008).  PKA signaling is known to influence 
cellular differentiation, ion channel activity, and plays a key role in the regulation of 
metabolism and triglyceride storage (Enns and Ladiges, 2010).  This single enzyme is able to 
regulate such numerous and diverse processes by having isoforms and splice variants for 
both the catalytic and regulatory subunits, each of which has its own spatial and temporal 
patterns of expression, and each of which confers a different mutant phenotype when 
knocked out in mice (Table 1).   
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Table 1. Different isoforms of regulatory and catalytic subunits of PKA. 
The C and R subunits are encoded by three and four different isoforms, respectively: C┙, C┚ 
and C┛ for the catalytic subunit, and RI┙, RI┚, RII┙ and RII┚ for the regulatory subunit 
(Burton et al., 1997).  Generally speaking, the ┙ isoforms are constitutively expressed in most 
tissues, whereas the ┚ isoforms are expressed at highest levels in the brain (Cadd and 
McKnight, 1989).  Specific responses to different hormones and neurotransmitters is also 
believed to be achieved by the subcellular compartmentalization of PKA (Harper et al., 
1985).  RII subunits are thought to contribute to this type of regulation, by anchoring PKA in 
close proximity to its substrates  through the binding of a family of A-kinase anchor proteins 
(AKAPs) (Lohmann et al., 1984; Rubin, 1994; Dell'Acqua et al., 1997). AKAPs anchor PKA by 
interacting with specific R subunits, and thus determine the subcellular localization of the 
PKA holoenzyme by what type of R subunit is present.  The type-I PKA holoenzyme 
contains RI subunits (RI┙ and RI┚) and is primarily cytoplasmic, while the type II 
holenzyme contains RII subunits (RII┙ and RII┚) and is associated with particulate 
subcellular fractions (McConnachie et al., 2006).   
Different and specific roles for the various subunits of PKA have been verified using  
conventional gene knockout mouse models.  Deletion of the C subunit causes perinatal 
lethality, or, in the case of survivors, severe growth retardation (Skalhegg et al., 2002), while 
up until recently, it was believed that knockout (KO) mice for C┚ are phenotypically 
indistinguishable from their WT littermates (Qi et al., 1996).  Complete loss of function of the 
R1┙ subunit leads to embryonic death early during gestation caused by abnormal 
mesodermal development (Amieux et al., 2002), while mice heterozygous for the knockout 
allele are predisposed to develop the myoxymas and endocrine tumors associated with 
Carney Complex (CNC) in humans (Kirschner et al., 2005).  RI┚ KO mice have deficiencies 
in synaptic plasticity (Brandon et al., 1995). 
Yet loss of function of various elements of the PKA signaling pathway have also been shown 
to have health and lifespan benefits.  Some of these beneficial PKA functions have been 
conserved evolutionarily from yeast to mammals, as evidenced by lifespan studies in yeast, 
worms, flies and mice.  In yeast, loss of function of CYR1, an adenylyl cyclase, increases 
lifespan (Longo, 2003) as do mutations in the GTP-GDP exchange factors CDC35 and 
CDC25.   Reduced function of TPK1, 2 and 3,  functionally redundant yeast PKA catalytic 
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subunits which are homologous to those in both mouse and human, also promotes 
longevity (Lin et al., 2000).  PKA activity also mediates age-related decline in flies (Yamazaki 
et al., 2007; Laviada et al., 1997), and recent studies in mice have described delayed cardiac 
aging and extended lifespan by deletion of the adenylyl cyclase, AC5 (Yan et al., 2007) and 
obesity resistance, increased lifespan and healthy aging by disruption of specific PKA 
subunit genes (Cummings et al., 1996; Enns et al., 2009a, 2009b). This chapter will focus on 
recent studies describing the health benefits of disruption of two different PKA subunits, the 
regulatory isoform RII┚, and the catalytic subunit C┚.  The proposed mechanisms behind 
these effects will be discussed as well as future work required to further investigate the 
potential of these subunits as pharmaceutical targets for the treatment of aging and age-
related disease in humans. 
2. Disruption of subunits of PKA leads to obesity resistance and leptin 
sensitivity 
Most mammals maintain their body composition within a narrow range of fat mass.  For 
example, following caloric restriction and a subsequent weight loss, rats increase food intake 
and decrease energy expenditure until they return to their original body weight (Mitchel 
and Keesey, 1977).  Likewise, obese rats which have been induced to overeat by electrical 
stimulation of the lateral hypothalamus, return to original body weights and blood glucose 
levels when the stimulus is removed (Steffens, 1975).  In order to accomplish energy 
homeostasis, an animal must be able to sense the amount of energy available in adipose 
tissue as well as sense and integrate opposing signals; it also must be able to regulate both 
energy intake and expenditure in response to this information.  The main tissues responsible 
for both the sensing of as well as the response to nutrient status are the hypothalamus, 
which controls body weight and appetite, brown adipose tissue (BAT), which controls 
thermogenesis and energy expenditure, and white adipose tissue (WAT), which is involved 
in energy storage (Cypess & Kahn, 2010).  The AC/cAMP/PKA pathway plays a major role 
in the genetic regulation of obesity and energy balance, as evidenced by mouse studies 
showing that disruption of specific PKA subunits leads to a more lean phenotype under 
'normal' conditions, as well as to obesity resistance when challenged with either a high 
fat/high carbohydrate diet  or with age-induced obesity. 
2.1.1 PKA and obesity resistance 
Disruption of the regulatory RII┚ subunit of PKA causes obesity resistance (Cummings et 
al., 1996). RII┚ is known to play a role in energy homeostasis.  The RII┚ regulatory isoform 
of PKA is abundant in brown and white adipose tissue and the brain, with limited 
expression elsewhere.  As mentioned earlier, these three tissues are the key players in the 
coordination of adiposity through regulation of energy storage, energy expenditure, and 
feeding behaviour.  Disrupting the RII┚ gene in these tissues does not cause any overt 
abnormalities, but RII┚ null mutants are remarkably lean, with fat pad weights about half 
that  of their wild-type littermates.  Body composition differences are only a result of a 
reduction in fat; these mutants do not suffer from decreases in muscle mass.  In addition, 
disrupting the RII┚ gene protects the obesity-susceptible C57/BL6 strain of mice from high 
fat/high carbohydrate (HF/HC) diet-induced both obesity and fatty livers (Cummings et 
al., 1996).  Obesity resistance caused by deletion of the RII┚ subunit has also been observed 
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in aging C57/BL6 mice, the WT which we have found to gain body weight post-maturity 
due to the accumulation of fat (Enns et al., 2009a).  At the peak of obesity, aging male WT 
mice, maintained on a regular diet, had 25% body fat, while RII┚ null mice only had about 
15% body fat; aging WT females and RII┚ null mice showed average maximum body fat 
percentages of about 30% and 15%, respectively.  This same study also found that WT mice, 
with age, developed livers up to twice their original size due to an accumulation of fat, and 
that disruption of RII┚ prevented this from occurring.  RII┚ thus represents a potential 
pharmacological target for the treatment of diet and age-induced obesity and fatty liver. 
Our studies have indicated that the C┚ catalytic subunit of PKA  also plays a role in 
maintaining a set point of adiposity (Enns et al., 2009b).  Young C┚ null mice appear overtly 
normal when maintained on a regular chow diet, but when challenged with a HF/HC diet, 
show resistance to the obesity and fatty liver disease suffered by their WT littermates.  This 
obesity resistance is not due to reduced food intake, which is similar between genotypes, 
nor to increased locomoter activity, which also shows no differences between genotypes.  In 
addition, knocking out C┚ protects aging mice on a regular diet from developing age-related 
obesity and fatty livers (Enns, In Press).   
2.1.2 PKA and thermogenesis  
The leanness of RII┚ null mutants had been thought in the past to be due to changes in PKA 
activity in brown adipose tissue (BAT).  BAT is a major contributor to non-shivering, diet-
induced thermogenesis, or heat production (Rothwell and Stock, 1979).  Thermogenesis is 
caused by the uncoupling of oxidative phosphorylation from ATP production in the 
mitochondria by uncoupling protein-1 (UCP1), which results in the energy from the proton 
motive force being dissipated as heat.   Increases in thermogenesis occur in response to 
marked increases in energy intake, such as those that occur in HF/HC diet-challenged mice.  
Non-shivering thermogenesis is in part regulated by the sympathetic nervous system, and 
can be stimulated by hormones such as norephinephrine and leptin.  It is known that PKA 
plays a mediating role in this process, phosphorylating perilipin, the main regulator of 
lipolysis, in response to these hormones (Souza et al., 2007).  Loss of the RII┚ subunit in BAT 
is associated with a compensatory increase in the RI┙ isoform, which has a higher affinity 
for binding cAMP.  The resultant increase in basal PKA activity in the BAT of RII┚ null 
mutants leads to an increase in UCP, an elevated metabolic rate and an increase in body 
temperature, suggesting that mutants are metabolically inefficient and waste food calories 
as heat (Cummings et al., 1996). The hypothesis that metabolic inefficiency is the cause of 
the RII┚ null lean phenotype is, however, confounded by data showing that disrupting 
UCP1 in RII┚ null mice reduces basal oxygen consumption but does not prevent the lean 
phenotype (Nolan et al., 2004). Regardless, the brain is believed to regulate adiposity in part 
through modulating sympathetic stimulation of PKA in BAT, resulting in changes in UCP 
expression and facultative energy expenditure (Himms-Hagen, 1990), and chronic activation 
of PKA in adipose tissue through ┚-adrenergic stimulation is being investigated for its 
potential in obesity therapy.  While UCP1 induction does not appear to be required for the 
maintenance of the lean phenotype in RII┚ null mice, it is still essential to sustain their 
increased basal oxygen consumption, a process important  to the regulation of energy 
expenditure and metabolic setpoint.  Understanding the role that RII┚ may play in this 
process is important for determining pharmaceutical targets that may also be useful for the 
development of anti-obesity drugs. 
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Altered thermogenesis does not appear to play a role in the PKA C┚ null obesity-resistant 
phenotype.  We did not find body temperature differences between C┚ null mice and their 
WT littermates, nor did we observe differences in UCP1 levels in the BAT between 
genotypes maintained on either a regular chow or a HF/HC diet.  Taken together, the RII┚ 
and C┚ mutant data indicates that while RII┚ is involved in regulating energy expenditure 
through induction of thermogenesis, upregulation of this process in particular is not 
essential in either of these mutants for obesity resistance to occur.   
2.1.3 PKA and WAT signaling 
In white adipose tissue (WAT), PKA is known to integrate a number of hormonal signals in 
order to regulate the lipolysis, or the catabolism of stored triglycerides into fatty acids and 
glycerol by hormone-sensitive lipase (HSL) (Planas et al., 1999).  Lipolysis is in part 
increased by ┚-adrenergic agonists, which stimulate PKA to both activate HSL (Stralfors et 
al.,1984; Anthonsen et al., 1998) as well as  promote its translocation to lipid droplets (Egan 
et al., 1992; Hirsch & Rosen, 1984). PKA also inhibits the expression of a number of lipogenic 
genes.  In RII┚ mutant WAT, there is an elevated basal rate of lipolysis when measured in 
vitro, and a blunted lipolytic response to ┚-AR stimulation that is observed both in vitro and 
in vivo.  It is unknown if these changes in WAT metabolism could play a role in the lean 
phenotype and obesity resistance observed in the RII┚ null mutants.  We have not yet 
characterized the WAT metabolism of C┚ null mutants.   
2.1.4 PKA and leptin sensitivity 
Studies on RII┚ using the leptin-deficient, obese ob/ob mouse (ob) indicate an important role for 
this particular PKA subunit in the leptin-dependent regulation of energy homeostasis 
(Newhall et al., 2005).  Leptin is a well-known peptide hormone that is produced by adipose 
tissue.  It plays a key role in the regulation of energy intake and energy expenditure, including 
appetite and metabolic rate.   The level of circulating leptin is directly proportional to the 
amount of fat stored in the body, and acts on receptors in the hypothalamus of the brain where 
it regulates the activity or synthesis of many neuropeptides that are important in appetite and 
metabolic control. The region of hypothalamus which serves to integrate signals controlling 
feeding and energy expenditure is called the arcuate nucleus region (ARC).  Two distinct 
populations of leptin-responsive neurons exist here: one that expresses the anabolic 
neuropeptides, NPY and agouti-related protein (AgRP) and one that expresses a precursor 
protein for the catabolic neuropeptide ┙-MSH, called proopiomelanocortin (POMC) (Cone 
2005; Morton et al., 2006). Both sets of neurons project into the paraventricular 
hypothalamus (PVH) where the Gs-coupled melanocortin receptor MC4R is activated by ┙-
MSH; this activation is antagonized by AgRP. Activation of the MC4R receptor is believed to 
decrease food intake and increase energy expenditure. PKA is a downstream mediator for 
many of these neuropeptides, (Schwartz et al., 2000; Flier, 2004).  Generally speaking, catabolic 
and anabolic neuropeptides signal through pathways that increase and decrease PKA activity, 
respectively.  Leptin inhibits NPY and AgRP release from the paraventricular nucleus, which 
normally leads to the activation of anabolic pathways through a decrease in PKA activity.  
Conversely, leptin stimulates the release of ┙-MSH, leading to an increase in PKA activity and 
the activation of catabolic pathways (Fig. 2). 
Studies on RII┚ null mice indicate that this mutation may confer leptin sensitivity. Even 
when fed only standard rodent chow, leptin serum levels in mutants were found to be 
www.intechopen.com
 Medical Complications of Type 2 Diabetes 
 
308 
threefold lower than for WT mice (Schreyer et al., 2001).  When maintained on the HF/HC 
diet, serum leptin levels increased differently between genotypes.  Both genotypes 
experienced elevations in serum leptin levels, but these increases were delayed in the 
mutants compared to WT, consistent with their delayed weight gain.  In spite of lower leptin 
levels, when standardized to body weight, food intake was actually slightly higher in the 
mutants, indicative of leptin sensitivity.   
This hypothesis was verified by knocking out the RII┚ subunit in other mouse mutants known 
to have problems with leptin signaling.  The ob mouse is hyperphagic, hypoactive, hypothermic 
and hyperinsulinemic (Bray & York, 1979), due to decreased expression of ┚-adrenergic 
receptors (┚-ARs) and UCP in BAT (Reichling et al., 1988; Collins et al., 1994).  The obese 
phenotype can be rescued by administration of leptin, which decreases their food intake and 
increases their metabolic rate in addition to restoring normal expression levels of adipose ┚-AR 
and UCP1 (Weigel et al., 1995; Mistry et al., 1997; Phelleymounter et al., 1995; Halaas et al., 1995; 
Campfield et al., 1995; Breslow & Berkowitz, 1997; Commins et al., 1999).  The phenotype of the 
ob mouse can also be rescued by knocking out RII┚.  The double mutant shows decreased body 
weight, increased energy expenditure, and activation of BAT resulting in increased 
thermogenesis (Newhall et al., 2004).  RII┚ is expressed in high levels in the hypothalamus 
(Planas et al., 1999).  An increase in basal PKA activity here, due to the disruption of the RII┚ 
subunit could lead to increased stimulation of leptin sensitive catabolic pathways.  
 
 
Fig. 2. Leptin signaling pathway as mediated by PKA. 
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Disruption of RII┚ also reverses the obesity syndrome found in agouti lethal yellow mice 
(Ay), which express agouti-related protein (AgRP) ectopically due to a genetic 
rearrangement at the agouti locus (Czyzyk et al., 2007).  Constitutive expression of AgRP, 
such as occurs in Ay mice, leads to hypoactivity, hyperphagy, hyperglycemia and 
hyperinsulinemia (Yen et al., 1994; Manne et al., 1995).  Disruption of RII┚ reduces both food 
intake and adiposity in these mice, indicating that the signaling pathway downstream of the 
agouti antagonism has been modified. It has been suggested that the known compensatory 
increase in the more cAMP-affinitive type I PKA, observed in RII┚ KO tissues, results in an 
overall increase in the basal activity of PKA that is downstream and thus independent of 
AgRP antagonism in hypothalamic neurons. 
We have also found that C┚ null mice are leptin sensitive in addition to being obesity 
resistant (In Press).  After several weeks of being maintained on a high fat diet, WT mice 
had elevated leptin serum levels that were 2.5-fold higher than C┚ null mutants.  In spite 
of lower serum leptin, mutants were found to be hypophagic and hypermetabolic, 
indicative of leptin sensitivity.  Although mutants maintained on a regular diet showed 
metabolic rates similar to WT, as determined using indirect calorimetry to measure the 
rate of  O2  consumption  (VO2 ), we did observe a higher metabolic rate in the C┚ null 
mutants compared to WT when both genotypes were maintained on a HF/HC diet 
(Enns, In Press). To directly test leptin sensitivity in the mutants, at the end of the 
HF/HC dietary challenge, both WT and mutants were injected with 4.0 ug leptin/g 
mouse, twice daily, for a period of a week.  Mutants, but not WT mice, showed 
significant weight loss, indicating that the WT mice had become leptin resistant on the 
HF/HC diet, while the C┚ null mice had not.  Leptin sensitivity in the C┚ null mice was 
verified by injecting young both mutants and WT mice, maintained on a regular diet, 
with leptin twice daily.  While weight loss and food intake were not affected differently 
between genotypes, by the end of the week-long injections, C┚ null mice were showing 
significantly higher rates of oxygen consumption compared to WT mice. Thus it is 
possible that C┚, like RII┚, acts downstream of leptin signaling in the hypothalamus.  
The C┚ gene encodes three isoforms: C┚1 is expressed in most tissues,  while C┚2 and 
C┚3 are neural-specific (Guthrie et al., 1997).  Measurements of brain PKA activity in the 
PKA C┚ null mutant have shown that knocking out all C┚ isoforms does not result in 
changes in total PKA activity, at least in the amygdala and hippocampus, as C┙ protein 
levels are upregulated in order to compensate.  It does, however, result in a 26% decrease 
in basal activity (without added cAMP) that may affect kinase activity at low cAMP 
concentrations (Howe et al., 2002).  This data would appear to be at odds with that 
showing that increased PKA activity is responsible for leptin sensitivity and obesity 
resistance in the RII┚ null mutant.  It is unknown how PKA activity is affected in the 
hypothalamus of C┚ null mice, but there are a number of possibilities. It may be affected 
differently than in other regions of the brain (ie. it may increase).  Conversely, C┙1 and 
C┚1 have diverged by about 10% in amino acid sequence in the mouse, but these 
sequence differences are strictly maintained with almost perfect fidelity across 
mammalian species (Uhler et al., 1986), suggesting that each has an important and 
unique function. If C┙ plays a specific role in the leptin signaling pathway compared to 
C┚,  it may be that the compensatory increase in C┙ activity in the C┚ null mutant is 
what is increasing signaling downstream of the MC4R receptor.   Regardless, this leptin 
sensitivity is likely the cause of the obesity resistant phenotype observed in both age and 
HF/HC diet-challenged C┚ null mutants. 
www.intechopen.com
 Medical Complications of Type 2 Diabetes 
 
310 
3. Disruption of subunits of PKA protects against diet-induced insulin 
resistance and dyslipidemia 
In addition to inducing obesity, the HF/HC diet used in our studies is known to induce 
diabetes in C57/BL6 mice (Surwit et al., 1988; Surwit et al., 1991). It is also common for mice 
fed this diet to develop hyperlipidemia, or an elevation of lipids in the blood, reflected by 
serum increases in low density and very low density lipoproteins (LDL and VLDL) (Kirk et 
al., 1995; Srivastava et al., 1991; Ishida et al., 1991; LeBoeuf et al., 1993).  Studies on HF/HC 
diet-fed PKA mutants have clearly illustrated an important role for PKA in the mediation of 
diet-induced insulin resistance and lipid disorder. 
3.1.1 PKA and insulin sensitivity 
RII┚ null mutants are resistant to HF/HC diet-induced insulin resistance.  Knocking out 
the RII┚ subunit of PKA resulted in mice with 26% lower serum insulin levels than WT 
when maintained on a regular diet. When maintained on a HF/HC diet for 15 weeks, both 
genotypes developed hyperinsulinemia, however insulin levels were much higher for WT 
mice (Schreyer et al., 2001). Blood glucose levels increased similarly for both genotypes 
when challenged with the HF/HC diet, but the observation that RII┚ null mice achieve 
similar glucose levels with less insulin indicates improved insulin sensitivity.  In keeping 
with this, loss of the RII┚ subunit resulted in improved glucose disposal in mice 
maintained on a regular chow diet, with lower blood glucose levels in the mutants 
compared to WT at all time points following a glucose injection. Also, while there were no 
differences in blood glucose between genotypes raised on a regular chow diet, RII┚ null 
mice were resistant to the marked reduction suffered by WT mice in the percentage of 
blood glucose cleared following an insulin injection after 15 weeks on the HF/HC diet.  
It is believed that since RII┚ expression is absent from pancreatic islets, these effects are not 
directly due to changes in insulin secretion in response to circulating glucose.  It  was 
proposed by Shreyer et al. that RII┚ null mice are at least in part protected from diet-induced 
insulin resistance due to their resistance to obesity under a HF/HC dietary challenge.  They 
were unable to test the null hypothesis due to a lack of sufficient number of RII┚ null mice that 
had white adipose tissue weights similar to those of their WT littermates; however, when 
insulin-mediated glucose disposal was corrected for differences in body weight, it was found 
that the HF/HC diet-fed RII┚ null mice cleared glucose in response to insulin at a similar rate 
to regular chow-fed mutants, while WT mice on the HF/HC diet showed decreased glucose 
disposal per gram mouse weight when compared with those on the regular diet.  This 
suggests that loss of RII┚ improves insulin sensitivity at least in part via a mechanism 
independent of adiposity.  One proposed mechanism is a reduction in PKA's known ability to 
antagonize insulin's activation of the mitogen-activated protein kinase (MAPK) cascade in 
adipose tissue (Sevetson et al., 1993).  Although it is known that in this particular tissue, the 
compensation for RII┚ by the more cAMP-affinitive RI┙ causes a four- to fivefold increase in 
basal PKA activity, is is possible that inhibition of this particular cascade, probably at the level 
of ras or raf, is dependent on an RII┚-containing PKA holoenzyme.   
Similarly, we have found that PKA C┚ also plays a role in insulin sensitivity.  As with RII┚ 
null mice, C┚ null mice are significantly protected against HF/HC diet-induced insulin 
resistance, showing improved glucose dispersal in response to insulin, compared to WT  
(Enns et al., 2009).  Interestingly, we have found that C┚ null mice are extremely sensitive to 
insulin compared to their WT littermates, even when maintained on a regular chow and 
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without major differences in adiposity levels.  In fact, on a regular diet, at least for females, 
young C┚ null mice show insulin sensitivity in spite of having slightly higher body fat 
percentages than WT. In other words, insulin sensitivity of the C┚ null mutant is 
independent of adiposity, and the loss of the C┚ null mutant has direct effects on insulin 
sensitivity.  Given the similarity between the C┚ and the RII┚ null phenotypes, it would be 
logical to propose that these two mutations are acting on insulin sensitivity via a similar 
mechanism. This would support the hypothesis of Shreyer et al. that PKA directly affects 
insulin sensitivity of adipose tissue, and that this particular mechanism is dependent on a 
specific subunit composition of PKA, specifically one containing either RII┚ or C┚.   
3.1.2 PKA and dyslipidemia 
Dyslipidemia, another problem often observed in conjunction with obesity and diabetes,  
was found to be reduced in both RII┚ and C┚ null mutants when challenged with a HF/HC 
diet. Plasma both total cholesterol as well as very low density and low density lipoproteins 
(VLDL and LDL) were significantly lower in RII┚ null mice compared to WT (Schreyer, 
2001).  C┚ null mutants, at least for males, when challenged with the HF/HC diet were 
resistant to the increases in LDL and VLDL and partially resistant to the increases in high 
density lipoprotein (HDL) observed in the serum of WT mice (Enns et al., 2009b).  Because 
insulin inhibits the assembly and release of VLDLs from the liver (Koo & Montminy, 2006), 
it is possible that the reduced serum VLDL levels seen in both types of mutants is an indirect 
effect of their insulin sensitivity.  Whether the marked loss of lipoproteins from the 
VLDL/LDL fraction of the diet-challenged RII┚ null mice and of lipoproteins from both the 
HDL and VLDL/LDL fraction of the diet-challenged C┚ null mice  is due to direct effects of 
the mutations on lipoprotein production or clearance, or is a result of indirect influences due 
to their insulin sensitivity or obesity resistance, is unknown.   
4. Disruption of PKA protects against cardiac hypertrophy and dysfunction 
Cardiac hypertrophy is an increase in the mass of the heart in response to and to 
compensate for an increased workload.  Prolonged stress leads to impaired diastolic and 
eventually systolic properties of the left ventricle, leading to heart failure (Shapiro & 
Sugden, 1996).  Altered PKA signaling has been implicated in cardiomyopathy by many 
previous studies (Enns et al., 2010; Lohse & Engelhardt, 2001).  For example, it is believed 
that the muscle-specific A-kinase Anchoring Protein (mAKAP) targets PKA to the 
perinuclear region of the cell where it can modulate cardiomyocyte size.   Inhibiting 
mAKAP expression suppresses the ability of leukemia inhibitory factor (LIF), which acts by 
increasing ERK5 activity, to induce cardiac hypertrophy (McConnachie et al., 2006).  
Deficiencies in PKA signaling have been linked to human cardiomyopathy due to reduced 
phosphorylation of downstream targets such as cardiac troponin I (Zakhary et al., 1999) and 
to preservation of cardiac function against pressure overload in mice (Okumura et al., 2003a; 
Okumura et al., 2003b).  We have found that the C┚ subunit of PKA plays an important role 
in the development of cardiac hypertrophy and dysfunction in response to both angiotensin 
II-induced as well as age-induced hypertension.   
C┚ null mice are resistant to angiotensin II- and age-induced cardiac hypertrophy and 
dysfunction (Enns et al., 2010; Enns et al., In Press). Angiotensin (ang) II is the effector of the 
renin-angiotensin system (RAS) and increases blood pressure by causing potent 
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vasoconstriction through stimulation of angiotensin receptors in the vascular system (Ito et 
al., 1995).  When ang II was administered to C┚ null mice and their WT littermates at a 
continuous rate and over a period of 4 weeks, both genotypes experienced similar and 
significant increases in both systolic and diastolic blood pressure.  In spite of experiencing 
similar hypertension, the hearts of the C┚ null mice were smaller and showed improved 
cardiac function in 4 of 5 echocardiographical parameters measured including left 
ventricular mass index (a measure of the thickness of the ventricular wall), fractional 
shortening (a measure of contractility of the left ventricle), ratio of early to late diastolic 
filling (a measure of compensation by the left atrium for left ventricle failure), and ratio of 
aortic to left atrial diameter (a measure of left atrial enlargement due to overcompensation 
for left ventricular failure).  We have also recently shown that as C57/BL6J mice age, they 
have a natural tendency to develop hypertension (Enns et al, In Press).  As with angiotensin 
II-challenged mice, aged (24 month-old) WT mice of this strain also experience significant 
cardiac hypertrophy, some showing hearts twice the size of those found in young (4 month-
old) mice.  In addition to enlarged hearts, aged WT mice, like those challenged with ang II, 
show thickened ventricular walls, reduced fractional shortening of the left ventricle, 
reduced early to late diastolic filling ratios, and enlarged left atria.  An additional parameter 
of global left ventricular function, myocardial performance index (MPI) was also found to 
worsen in aging WT mice. Disruption of the C┚ subunit did not protect aging C57/BL6 mice 
from hypertension, but did make mice resistant to  both the cardiac hypertrophy 
experienced by the aging WT mice, as well as to their decline in cardiac performance in all 
parameters measured.  Effects of disruption of RII┚ on age and ang II-induced cardiac 
decline have not yet been assessed.  
PKA C┚ thus appears to play an important role in the mediation of hypertension and its 
myopathological effects.  The ┚-adrenergic (┚-AR)/adenylyl cyclase/PKA pathway, central 
to stimulating cardiac function, is known to be dysfunctional in heart failure (Bristow et al., 
1982).  Blockade of ┚-AR receptors improves survival in heart failure patients (Bristow, 2000) 
and transgenic mouse studies have shown that chronic activation of the cAMP-PKA 
pathway by cardiac-specific overexpression of ┚-AR, Gs┙, and the ┙-catalytic subunit of 
PKA result in cardiomyopathy (Lohse & Engelhardt, 2001; Antos et al., 2001).  PKA is 
known to cause cardiac hypertrophy in response to elevation of cAMP by ┚-adrenergic 
agonists (Rockman et al., 2002).  There are, however, conflicting data in the literature to 
support the idea that activation of the ┚-AR/cAMP/PKA pathway  may play a protective 
role in response to hemodynamic overload.  In humans, phosphorylation of troponin I (TnI) 
by PKA is reduced in dilated cardiomyopathy (Zakhary et al., 1999), and in mice, 
overexpression of two types of cardiac adenylyl cyclases results in improved cardiac 
function (Lipskaia et al., 2000; Gao et al., 1999).   The RII┚ mutant is thought to be sensitive 
to ┚-AR activation (McKnight et al., 1998; Montovani et al., 2009), an idea supported by their 
exaggerated response to amphetamine (Brandon et al., 1998).  Given the other phenotypic 
similarities between the RII┚ and C┚ mutants, it is possible that the C┚ null mouse has a 
similar sensitivity, and that an overactive ┚-AR pathway is protecting their hearts against 
pressure overload.   
PKA plays many other roles in cardiac signaling, and any of these may play a role in cardiac 
hypertrophy and dysfunction.  For example, activation of cAMP/PKA signaling in the heart 
has been shown to inhibit smooth muscle proliferation (Indolfi et al., 1997).  Calcium 
signaling pathways also play a role in cardiac hypertrophy (Passier et al., 2000; Minamisawa 
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et al., 1999), supported by the finding that in the presence of hypertension, its development 
can be prevented by L-type calcium channel blockers (Zou et al., 2002).  PKA has multiple 
downstream targets involved in calcium signaling in the heart, including the L-type Ca2+ 
channel in the sarcolemma, the ryanodine receptor (RyR2), and phospholamban in the 
sarcoplasmic reticulum (Antos et al., 2001).  The C┚ subunit of PKA may play a specific role 
in the activation of one or more of these substrates. 
5. PKA and longevity 
Given that disruption of either the RII┚ or C┚ subunit of PKA in mice confers resistance to a 
number of health problems associated with aging, including obesity, leptin and insulin 
resistance, and cardiac hypertrophy and dysfunction, it was of interest to determine 
whether or not knocking out either of these genes would also lengthen the murine lifespan.  
Lifespan studies revealed an increase in both the median and maximum lifespans for RII┚ 
null males with an increase in median lifespan from 884 days to 1005 days, and an increase 
in the 80% lifespan (80% deaths of the cohort) from 941 to 1073 days.  There was no 
difference in either median or 80% lifespan between genotypes in females (Enns et al., 
2009a).  Lifespan cohorts for C┚ null mice showed no effect on either the median or 
maximium lifespan for females, and a reduced lifespan for C┚ null males. 
Whether or not the attenuation of an age-related health problem translates to an increase in 
lifespan for a particular strain of mouse depends on its contribution to that strain's probable 
cause of death.  We have determined that adiposity plays a significant role in the lifespan of 
the male, but not the female C57BL/6J WT mouse (Enns et al., 2009a).  As mentioned earlier, 
this strain of mouse is susceptible to age-related obesity,  and individuals continue to put on 
body weight in the form of body fat for many months post-maturity. This gain in adiposity 
was found to be variable between individuals, however, and when the lifespan of individual 
WT mice was plotted against their maximal body weight, a strong correlation was found for 
males (R2=0.4795), but not for females (R2=0.0369). Age-related obesity is thus a strong risk 
factor for mortality in male C57BL/6J mice, and it is not surprising that disruption of a gene 
such as RII┚, that removes this risk factor would also lengthen their lifespan . 
Lifespan analyses can be an indicator for whether or not disrupting a gene also confers 
detrimental effects.  For example, the shortened lifespan of the C┚ null male mouse implies 
that this PKA subunit plays a role in other necessary functions.  When mice heterozygous 
for the C┚ null mutation are bred , male homozygous nulls are born at a lower than 
expected frequency, indicating that the C┚ subunit of PKA may be important to males 
during their embryonic development.  That disruption of either RII┚ or C┚ does not 
lengthen the female lifespan is not necessarily surprising, given that we found no correlation 
between adiposity and lifespan for C57BL/6J females.  However, it can also be said for 
females that there appear to be no detrimental effects, at least those which would impact 
lifespan, of disrupting either of these PKA subunits.  This is important for validating either 
of these subunits as a potential pharmaceutical target for the treatment of age-related 
disease in humans. 
6. Conclusions 
The C┚ and RII┚ subunits of PKA represent promising pharmaceutical targets for the 
treatment of metabolic syndrome, a name for a group of risk factors that together increase 
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the risk of coronary disease, stroke, and type II diabetes and a problem which is rapidly 
becoming the predominant cause of poor health and reduced lifespan in industrialized 
nations.  Mouse mutants lacking either of these subunits display a number of health 
benefits, including resistance to age and diet-induced obesity, protection against age and 
diet-induced leptin and insulin sensitivity, and resistance to cardiac hypertrophy and 
dysfunction.   
The potential of a protein or protein subunit as a pharmaceutical target depends on whether 
or not its disruption also causes negative effects.  Lifespan analyses show that in C57BL/6J 
mice, there appear to be no major detrimental health effects either on males and females 
from disrupting the RII┚ subunit, or on females from disrupting the C┚ subunit.    
Disrupting the C┚ subunit in males appears to carry some detriment, possibly during 
embryonic development, that affects the overall lifespan of the mouse, but pharmaceutical 
treatment of obesity and aging in humans would presumably occur beyond the age of 
maturity.  Conditional mouse mutants need to be constructed to determine if knocking out 
the gene later in life removes the detrimental effects on the male PKA C┚ null lifespan. 
Future work needs to address the many unanswered questions that have arisen from these 
studies.  Are the phenotypes we are observing the result of the loss of the RII┚ and C┚ 
subunits, or of the known compensation by other PKA isoforms?  Do these subunits affect 
the nature of the downstream targets of PKA, and if so, what are those targets, and what is 
their potential for pharaceutical targeting?  Is leptin sensitivity the sole cause of the obesity 
resistance in the RII┚ and C┚ null mutants, or are there other mechanisms? By what direct 
mechanism is RII┚ and C┚ influencing insulin sensitivity, and what is its specific 
contribution to healthy aging and lifespan?  What are the mechanisms behind the resistance 
to cardiac hypertrophy and dysfunction?   Finally, how can we discover or develop 
pharaceuticals that will specifically target these PKA isoforms?  Answering these questions 
will both validate the potential of these subunits as pharmaceutical targets, as well as 
identify new potential targets for the treatment of age-related metabolic syndrome in 
humans. 
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